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Summary
 Background: Coronary artery calciﬁ cation (CAC) is an important indicator of future coronary artery disease 
events. Since elevated blood pressure (BP) is an important predictor of CAC, genetic polymor-
phisms in the renin-angiotensin system and their interaction may play a role in explaining CAC 
quantity variation.
 Material/Methods: As part of the Epidemiology of Coronary Artery Calciﬁ cation Study, 166 asymptomatic women and 
166 asymptomatic men were genotyped for the insertion/deletion polymorphism in the angiotensin-
converting enzyme (ACE) gene and the –6 promoter polymorphism of the angiotensinogen (AGT) gene. 
We used a novel method to detect gene-gene interaction and compared it to the standard two-way 
analysis of variance (ANOVA) method.
 Results: Based on a two-way ANOVA model, there was no evidence for epistasis for either systolic BP or 
CAC in either men or women. However, using a novel method, we found evidence of signiﬁ cant 
gene-gene interaction in systolic BP in men and gene-gene interaction in both systolic BP levels 
and CAC quantity in women.
 Conclusions: Our study demonstrates that new methods of assessing epistasis maybe important in understanding 
the complex genetics of systolic blood pressure as well as subclinical coronary atherosclerosis.
 key words: epistasis • blood pressure • gene-gene interactions • coronary artery calciﬁ cation • 
statistical
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BACKGROUND
Although there have been many studies of candidate genes 
for hypertension and coronary artery disease (CAD), the vast 
majority of studies have focused on risk factors or clinical 
end points and have only investigated single-gene effects. 
As we move into a more genomic era of studying the genet-
ic architecture of complex diseases like CAD, its subclinical 
phenotypes, and its risk factors, it is likely that the interac-
tions between genes will play a greater role than the contri-
bution of any single gene [1]. One limitation to progress in 
this area arises from the limitations of our methods of de-
tecting gene-gene interactions and their impact on disease 
risk. For example, traditional statistical models of interac-
tion (e.g., a two-way analysis of variance with interaction) use 
the phenotypic variance explained by the interaction (mean 
square due to interaction) as the measure of the contribu-
tion of interaction to the trait of interest. This traditional 
approach for detecting interaction has been challenged by 
Cheverud and colleagues [2,3] because it does not test the 
main underlying null hypothesis of epistasis – that is, the dis-
tance between the genotypic means estimated for one locus 
does not change across the genotypic background marked 
by a second locus [4]. This view of epistasis has been called 
a “physiological epistasis” model because it focuses on the 
average phenotypic value of individuals carrying a particu-
lar multilocus genotype and does not depend on the popu-
lation frequency of the genotype class. In traditional statisti-
cal genetics, deﬁ nitions of interaction rely on the estimation 
of the mean square value due to interaction after frequen-
cy dependent estimation of the mean square value due to 
the main effects of each genetic locus [5,6].
The term epistasis has been used for more than 100 years. 
In the classical sense, epistasis refers to the masking of the 
phenotypic effects of one gene by the effects of a second 
gene and a gene is epistatic when its presence suppress-
es the effect of the other gene. This original deﬁ nition of 
epistasis is biological, rather than statistical (Moore, 2005) 
[7]. Today, we recognize that gene-gene interactions can 
act directly to change transcription or translation levels or 
indirectly, by way of their protein products, to alter pheno-
types in ways that are separate from their independent ef-
fects (Thorton-Wells et al., 2004) [8]. What we are referring 
to here is not classical epistasis; but rather, the idea that mul-
tiple polymorphisms can affect phenotypes in complex ways 
not necessarily captured by standard analytical approaches 
to interactions (Thorton-Wells et al., 2004) [8].
In the study presented here we illustrate the differences be-
tween the traditional statistical genetics approach and “phys-
iological epistasis” approach by testing for epistatic effects 
of the angiotensin-converting enzyme (ACE) insertion (I)/de-
letion (D) polymorphism and in the anginotensiogen (AGT) 
promoter polymorphism at position –6 on interindividual 
variation in systolic blood pressure (SBP) and coronary ar-
tery calciﬁ cation (CAC) quantity levels.
CAC is an active component of atherosclerosis, the primary 
cause of CAD [9,10]. CAC can be accurately and non-inva-
sively measured using electron beam computed tomography 
(EBCT) [11,12]. A direct relationship exists between CAC 
and both histological and in vivo intravascular ultrasound 
measures of atherosclerotic plaque [13–17]. EBCT measure-
ment of CAC is a highly sensitive and speciﬁ c method for 
detecting obstructive CAD [18]. Measures of the presence 
and quantity of CAC predict future CAD end points in both 
symptomatic and asymptomatic individuals [19–22].
Little is known about the genetic basis of CAC. Before ad-
justing for any risk factors, 43.5% of the variation in CAC 
quantity was attributable to genetic factors [23]. After ad-
justing for risk factors, including SBP, 41.8% of the residu-
al variation in CAC quantity was attributable to genetic fac-
tors [23]. There have been few candidate gene studies in 
CAC measured by EBCT [24,25] and only one genetic link-
age study has been published [26]. Lipoprotein(a), which 
has a strong genetic component, is associated with both the 
presence and quantity of CAC [27].
Important predictors of CAC include measures of high 
blood pressure [28–30] and pulse pressure which are under 
both environmental and genetic control. The renin-angi-
otensin system (RAS) plays a cardinal role in salt and water 
homeostatsis and vascular tone regulation, and is impor-
tant in the pathobiology of hypertension and vascular dis-
ease [31,32]. Given the high prevalence of prehypertension 
and hypertension in the United States [33], many studies 
have focused on genes for blood pressure regulation and 
the organ damage resulting from uncontrolled high blood 
pressure. Two well-studied genes that are part of RAS are 
AGT on chromosome 1 and ACE on chromosome 17. A com-
mon variant in the AGT gene is an A®G substitution 6 base 
pairs upstream from the site of transcription initiation in 
the proximal promoter region. Inoue et al. [34] found that 
the AGT-6 polymorphism is in very tight linkage disequilib-
rium with the threonine to methionine polymorphism at 
residue 235 (M235T), an AGT polymorphism that numer-
ous studies have focused on as a candidate gene for hyper-
tension and CAD [31,35–40]. The most widely studied pol-
ymorphism in the ACE gene is an insertion(I)/deletion(D) 
that has been reported to be associated with increased lev-




The sample for this analysis originated from the Epidemiology 
of Coronary Artery Calciﬁ cation (ECAC) study [46]. 
Participants in this study were recruited from the Rochester 
Family Heart Study, a community-based cross-sectional study 
of the genetic epidemiology of CAD and essential hyperten-
sion in Rochester, Minnesota [47,48]. Individuals were re-
cruited into the ECAC Study independent of risk factor sta-
tus and were at least age 20 at the time of recruitment, not 
pregnant or lactating, and never had coronary or non-coro-
nary heart surgery. Each of the 1,240 ECAC participants un-
derwent a physical examination, donation of a blood sam-
ple, review of medical records and an EBCT examination 
during a visit to the Mayo Clinic. The study protocols were 
approved by the Mayo Clinic and University of Michigan 
Institutional Review Boards. All individuals provided their 
written informed consent.
During an interview, participants reported current med-
ication use and history of physician-diagnosed hyperten-
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sion. Standard enzymatic methods were used to measure 
total cholesterol [48]. Body mass index (BMI) was calcu-
lated (weight/height2; (kg)/(m2)). SBP and diastolic blood 
pressure (DBP) levels were measured in the right arm with 
a random-zero sphygmomanometer (Hawksley and Sons). 
Three measures at least two minutes apart were taken and 
the average of the second and third measurements was 
used. A total of 222 females and 239 males had genotype 
data for both the ACE and AGT polymorphisms. Thirty 
women and 40 men less than 30 years old were excluded 
from this analysis because of the low prevalence of detect-
able CAC in younger individuals [49]. Another 3 men had 
a history of myocardial infarction or stroke and were ex-
cluded from analyses. Since some participants were mem-
bers of the same family and all analyses were sex-speciﬁ c, 
one woman and one man from each family were randomly 
selected for the present analyses. The ﬁ nal sample includ-
ed 166 unrelated women and 166 unrelated men who were 
asymptomatic for CAD.
Genotype measurement
Genotyping of the candidate gene polymorphisms was car-
ried out by subjecting 20 ng aliquots of genomic DNA for 
each individual in the study to PCR ampliﬁ cation and sub-
sequent restriction-endonuclease digestion. DNA was ex-
tracted from blood drawn at the time of the physical exam. 




CGGCAGGCTTCTTCCATC-3’] (Inoue et al., 1997). The 
primers used for the ACE D/I polymorphism in intron 16 
were [5’-CTGGAGACCACTCCCATCCTTTCT-3’] and [5’-
GATGTGGCCATCACATTCGTCAGAT-3’] [50]. The inser-
tion corresponds to an alu repetitive sequence and is 287 
bp long [50]. The fragments were then visualized by the use 
of ethidium-bromide staining after electrophoresis on 10% 
vertical acrylamide gels. Samples initially scored as hetero-
zygotes were subjected to successive enzyme digestions and 
rescored to minimize the possibility of mistypings due to in-
complete digestions. Genotypes were scored separately by 
two trained laboratory workers and any discrepant typings 
were subjected to examination by a third party. All labora-
tory personnel were blind to the CAC and risk factor sta-
tus of individuals being genotyped. All genotyping was per-
formed under the supervision of Dr. Eric Boerwinkle at the 
University of Texas, Houston.
Coronary artery calciﬁ cation measurement
Quantity of CAC was measured using an Imatron C-100 or 
C-150 EBCT scanner (Imatron Inc., South San Francisco, 
California). A scan run consisted of 40 contiguous 3-mm 
thick tomograms initiating at the root of the aorta and pro-
ceeding caudally to the apex of the heart. Each tomogram 
took 100 msec of scan time. All images were triggered at 
end-diastole using electrocardiographic gating and were ac-
quired during two to four breath holds.
Tomograms were initially scored by a radiologic technolo-
gist using an automated scoring system [51]. CAC was de-
ﬁ ned as a hyperattenuating focus of ≥4 contiguous pixels in 
size, within 5 mm of the arterial midline, and with a com-
puted tomography (CT) number above 130 Hounsﬁ eld 
units (HU) throughout the focus. An experienced radiol-
ogist then reviewed the technical quality and scoring accu-
racy of each tomogram before making interpretations re-
garding the ﬁ ndings. Quantity of CAC was deﬁ ned as the 
area of CAC in mm squared totaled over all foci in four epi-
cardial arteries (left main, left anterior descending, left cir-
cumﬂ ex, and right coronary arteries).
Statistical analysis
We identiﬁ ed a group of unrelated men and women. In this 
group of men and women, we tested the null hypothesis of 
Hardy-Weinberg equilibrium for the AGT and ACE polymor-
phisms using chi-square tests. All subsequent analyses were 
sex-speciﬁ c. All statistical analyses were performed using SAS 
statistical software (Version 8.02, SAS Institute, Cary, NC).
The logarithm of the quantity of CAC plus the value one 
(log [CAC area +1]) was taken in order to reduce skewness 
in the distribution of CAC quantity. Since blood pressure 
is such a signiﬁ cant predictor of CAC [28] we investigated 
the epistatic effects of ACE and AGT polymorphism on log 
(CAC area +1) adjusting for SBP, as well as age, age2, hyper-
tension status and use of blood pressure lowering medica-
tions and on SBP adjusted for age, age2, hypertension status 
and use of blood pressure lowering medications.
One-way analysis of variance (ANOVA) was used to test for 
effects of each polymorphism alone on the covariate adjust-
ed SBP levels and the covariate adjusted CAC levels. Two-
way ANOVA was used to test for interaction effects between 
the AGT and ACE polymorphisms on the covariate adjusted 
SBP levels and the covariate adjusted CAC levels by coding 
AGT and ACE genotypes as class variables, with 2-degrees 
of freedom for each main effect test and 4-degees of free-
dom for the test of interaction effects.
As an alternative to the traditional statistical genetics meth-
ods of detection of interaction, the method developed by 
Cheverud and Routman [2] was used to estimate and test 
for the sum of the individual epistatic effects between AGT 
and ACE on covariate adjusted SBP levels and covariate ad-
justed CAC levels. This method allows the partition of each 
of the nine two-locus genotypic values (i.e., the two-way cell 
means) into nonepistatic and epistatic values that are not 
weighted by allele frequencies. Using the Cheverud and 
Routman notation, let Gijkl be the average phenotypic val-
ue for individuals with genotypes ij at the AGT locus and 
kl at the ACE locus.
Then the marginal genotypic values, or single-locus values 
(SLV), for AGT (Gij..) are calculated as: 
Gij..= (Gij11 + Gij12 + Gij22)/3,
while the marginal genotypic values, or single-locus values 
(SLV), for ACE (G..kl) are calculated as:
G..kl = (G11kl + G12kl + G22kl)/3.
Non-epistatic values (neijkl) are calculated as:
neijkl = Gij.. + G..kl – G….
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where G…. is deﬁ ned as the unweighted average of the nine 
genotypic values. The epistatic value (eijkl) for each two-locus 
genotype is simply the difference between the genotypic val-
ue and the non-epistatic value for that particular genotype ij 
at the ﬁ rst locus and genotype kl at the second locus: 
eijkl = Gijkl – neijkl.
The error variance for a particular eijkl, say e1111, is calculat-
ed as follows: 
V(e1111) = [16V(G1111) + 4[V(G1112) + V(G1122) + V(G1211) + V(G2211)]
+ V(G1212) + V(G1222) + V(G2212) + V(G2222)]/81.
Note that this formula can be used to derive the remain-
ing eight variances. In general, 16 is the coefﬁ cient for the 
genotypic value variance of the two-locus genotype of in-
terest, 4 is the coefﬁ cient for the genotype value variances 
with the same genotype as the genotype of interest at one 
locus but not the other, and 1 is the coefﬁ cient for the oth-
er 4 genotypic value variances. A measure of the overall lev-
el of epistasis (E2) is the sum of the squares of the individ-
ual epistatic values: 

















The signiﬁ cance of the overall level of epistasis can be tested 
using an F-test with 4, N-9 degrees of freedom (N = sample 
size) that compares the epistasis mean-square error (EMS) 
and residual mean-square error (RMS)





















2/N)]/4 and RMS is the pooled within-geno-
type variance. The RMS can be obtained from a two-way 
ANOVA with the main effects and interaction effects of the 
two loci. Individual tests of epistatic values can be conduct-
ed to identify the particular set of genotypes that are inter-
acting using the T-statistic, T= eijkl/V(eijkl).
RESULTS
In this sample, the 166 asymptomatic unrelated men ranged 
in age from 30 to 75 years with a mean of 49 years. The 166 
asymptomatic unrelated women ranged in age from 30 to 
82 years with a mean of 50 years (Table 1). The descriptive 
statistics for height, weight, BMI, SBP, DBP, fasting plasma-
cholesterol levels, CAC, hypertension status, and use of blood 
pressure lowering medications are also presented in Table 1. 
Overall, the frequency of the AGT G allele was 0.602 and 
the frequency of the ACE I allele was 0.446 in the sex-com-
bined unrelated sample. The chi-square tests for the null 
hypotheses of Hardy-Weinberg equilibrium were not reject-
ed for either the AGT or the ACE polymorphisms (P=0.569 
Men (n=166) Women (n=166)
Mean ±SD Range Mean ±SD Range
Age, years  48.7±9.1  30.2–75.9  49.6±9.0  30.1–82.0
Weight, kg  89.5±14.0  56.4–151.5  72.8±15.2  46.8–132.5
Height, cm  179.0±5.9  163.1–195.6  164.0±5.5  148.9–180.1
BMI, kg/m2  27.9±4.1  20.6–47.6  27.1±5.6  18.4–50.1
SBP, mmHg  118.5±14.4  92.5–175.0  116.7±15.0  85.0–179.0
DBP, mmHg  78.2±9.5  54.0–105.0  74.6±8.5  56.0–104.0
Cholesterol, mg/dl  192.9±34.6  115.0–309.0  188.0±38.7  68.0–352.0
CAC Area  23.7±64.6  0.0–510.0  7.2±32.1  0.0–329.8
Log(Area +1)  1.5±1.7  0.0–6.2  0.5±1.2  0.0–5.8
Hypertension,% 17.5% 10.9%
Blood pressure lowering medications,% 9.0% 7.2%
Prevalence of detectable CAC,% 53.0% 21.1%
Table 1. Descriptive characteristics of the sample.
Men GG GA AA Total
DD 17 23 11 51
DI 30 43 14 87
II 12 10 6 28
Total 59 76 31
Women GG GA AA Total
DD 22 20 2 44
DI 27 50 14 91
II 10 18 3 31
Total 59 88 19
Table 2. Two locus genotype frequencies for men and women.
Med Sci Monit, 2006; 12(4): CR150-158 Kardia SLR et al – Epistatic effects on BP and CAC
CR153
CR
and P=0.121, respectively). The two-locus allele frequencies 
for men and women are given in Table 2.
In men, SBP was adjusted for age, age2, hypertension status, 
and use of blood pressure lowering medications which ac-
counted for 51% of the variation in SBP (data not shown). 
Based on one-way ANOVA there was no association be-
tween either polymorphism and adjusted SBP levels in men 
(P=0.739 for AGT; P=0.246 for ACE). There was no evidence 
for epistasis based on two-way ANOVA (P=0.541). However, 
using the physiological epistasis model, we found signiﬁ -
cant evidence of epistasis in adjusted SBP levels in men in-
volving the GG/II and GA/II genotype (P<0.05) (Table 3A 
and Figure 1A).
In men, log (CAC area +1) was adjusted for age, age2, SBP, 
hypertension status, and use of blood pressure lowering 
medications which accounted for 18% of the variation in 
this trait. There was evidence for a possible association 
between ACE and adjusted CAC quantity based on one-
way ANOVA (P=0.051). The two-locus genotypic values in 
Figure 2A suggest a positive main effect of the ACE II gen-
otype on CAC quantity regardless of AGT-6 genotype. The 
AGT-6 polymorphism was not associated with a signiﬁ cant 
main effect on CAC quantity (P=0.631). There was no evi-
dence of a signiﬁ cant gene-gene interaction between ACE 
I/D and AGT-6 polymorphisms on adjusted CAC levels in 
this sample of men based on the physiological epistasis 
model used here (Table 3B and Figure 2A) or a two-way 
ANOVA (P=0.426).
In women, the covariates age, age2, hypertension status, and 
use of blood pressure lowering medications explained 40% 
of the variation in SBP. Based on one-way ANOVA there was 
no association between either polymorphism and adjusted 
SBP levels in women (P=0.838 for AGT; P=0.799 for ACE). 
There was also no evidence for epistasis using the two-way 
ANOVA (P=0.563). With respect to the role of epistasis in 
determining adjusted SBP levels we found that the GG/DD, 
GA/DD, AA/DD, GG/DI, GA/II, and AA/II were associated 
with statistically signiﬁ cant epistatic effects using the phys-
iological epistasis method (P=0.033) (Table 3B and Figure 
1B). Here the ACE genotype only has an effect when the 
AGT genotype is AA.
In women, the covariates age, age2, SBP, hypertension status, 
and use of blood pressure lowering medications account-
ed for 35% of the variation in log(CAC area+1). There was 
no association between either polymorphism and adjusted 
CAC levels based on one-way ANOVA (P=0.166 for AGT; 
P=0.544 for ACE). The AGT-6 and ACE I/D two-locus gen-
otypic values of adjusted log (CAC +1) are given in Table 
4B and illustrated Figure 2B. The crossover in the plot is 
suggestive of additive by additive epistatic effects in women. 
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The mean adjusted log(CAC area+1) for women with the 
ACE II genotype is lower than or comparable to the other 
ACE genotypes for women with the AGT GG or AG geno-
types. However, it is higher than the other ACE genotypes 
for women with the AGT AA genotype. In this case it is not 
possible to answer the question, does the ACE I allele tend 
to higher or lower CAC. The answer is higher if a person is 
AGT AA and lower if they are AGT GG.
Using a two-way ANOVA model, the F-test for interaction be-
tween the AGT-6 and ACE I/D polymorphisms on CAC was 
not statistically signiﬁ cant in women (P=0.153). The over-
all F-test for interaction using the Cheverud and Routman 
method [2] was marginally statistically signiﬁ cant (P=0.052). 
The estimates of the nonepistatic and epistatic values along 
with the standard errors and associated t-values for individ-
ual epistatic values for adjusted log(CAC area+ 1) are dis-
played in Table 4B. The individual epistatic values that were 
each statistically signiﬁ cant (P<0.05) were GG/DD, GA/DD, 
AA/DD, GG/DI, GG/II, AA/DI and AA/II indicating that 
the genotypic values associated with 7 of the 9 two-locus gen-
otype classes were affected by epistatic effects. Interestingly, 
in women, the signiﬁ cant epistatic effects on SBP demon-
strated some differences as compared to CAC.
DISCUSSION
It is well known that common chronic diseases such as CAD, 
hypertension, and diabetes have multifactoral inheritance 
patterns. Over the last 15 years there has been a plethora 
of single gene association studies aimed at understanding 
the genetic architecture of these common diseases. Many, 
or perhaps most, of the ﬁ ndings from single gene associa-
tion studies have not been replicated by other studies. From 
a single gene, Mendelian perspective of disease, this lack 
of replicability calls into question the validity of the genet-
ic inferences made from the individual studies. From the 
perspective of what we know of the genetic architectures of 
complex traits studied in animals and plants [52,53], this 
lack of repeatability is expected. Differences in the joint fre-
quency distribution of genetic and environmental factors 
across samples, coupled with the substantial role of inter-
action between these factors, makes for a very complex ge-
Genotypic values
GG GA AA SLV
DD 118.58 118.32 117.65 118.18
DI 119.40 119.18 120.38 119.65
II 119.62 110.99 116.15 115.59
SLV 119.20 116.16 118.06
Nonepistatic values
GG GA AA
DD 119.57 116.54 118.43
DI 121.04 118.01 119.90
II 116.98 113.94 115.84
Epistatic values ±standard errors
GG GA AA
DD  –1.00±1.10  1.78±1.07  –0.78±1.26
DI  –1.65±1.00  1.18±0.95  0.47±1.12
II  2.64±1.17  –2.95±1.40  0.31±1.62
t-values (ratio of epistasis value to standard error)
GG GA AA
DD –0.91 1.66 –0.62
DI –1.65 1.24 0.42
II 2.26* –2.00* 0.19
Table 3A.  Genotypic, nonepistatic and epistatic values for men for 
systolic blood pressure (in mm Hg) adjusted for age, age2, 
hypertension status, and use of blood pressure lowering 
medications. E2=24.858; F=1.005; P=0.407.
* Indicates statistically signiﬁ cant at α=0.05;
SLV – denotes the single locus values.
Genotypic values
GG GA AA SLV
DD 1.75 1.33 1.48 1.52
DI 1.36 1.47 0.90 1.24
II 2.25 2.17 2.00 2.14
SLV 1.79 1.66 1.46
Nonepistatic values
GG GA AA
DD 1.67 1.54 1.35
DI 1.40 1.27 1.07
II 2.29 2.16 1.97
Epistatic values ±standard errors
GG GA AA
DD  0.08±0.19  –0.21±0.17  0.13±0.21
DI  –0.03±0.15  0.20±0.15  –0.17±0.19
II  –0.04±0.20  0.01±0.20  0.04±0.23
t-values (ratio of epistasis value to standard error)
GG GA AA
DD 0.41 –1.26 0.64
DI –0.24 1.38 –0.88
II –0.22 0.03 0.16
Table 3B.  Genotypic, nonepistatic, and epistatic values for men for 
log(CAC area+1) adjusted for age, age2, systolic blood 
pressure, hypertension status, and use of blood pressure 
lowering medications. E2=0.143; F=0.366; P=0.833.
SLV – denotes the single locus values.
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netic architecture where similar genes will show different 
results in different populations [52;54–57].
New statistical approaches that incorporate multiple loci 
in candidate gene analysis are necessary in order to de-
tect small context-speciﬁ c genetic effects in the coronary 
atherosclerosis process. In general, the analysis of variance 
methods are more conservative for testing interaction ef-
fects than the physiological epistasis method presented by 
Cheverud and Routman [2]. Speciﬁ cally, it has been shown 
that as allele frequencies deviate from 0.5, the additive and 
dominant components of variability for a single locus sub-
sume more and more of the variability that is actually due 
to epistasis [3]. This phenomena results in smaller estimates 
of the component of variability due to epistasis than is ac-
tually observed in the genotypic mean differences and this 
results in reduced power to detect gene-gene interactions 
using the analysis of variance methods.
While numerous studies have examined the separate, sin-
gle-site effects of polymorphisms in the AGT and ACE genes 
and their effect on CAD risk factors and outcomes, few have 
explored epistatic effects between the two polymorphisms. 
To our knowledge, the only other study to investigate inter-
action effects between AGT and ACE on CAD examined the 
prevalence of myocardial infarction (MI) in a case-control 
study based on the population of St. Petersburg, Russia [58]. 
The cases were 198 MI survivors at least age 55 years. Sex of 
these survivors was not described. Controls were males be-
tween 6–17 years. The researchers reported that the main 
effects for the M235T and ACE I/D polymorphisms were 
not signiﬁ cant, but they found signiﬁ cant evidence of epista-
sis (the frequency of double homozygotes TTII was great-
ly increased in the group of MI patients as compared with 
those in the control group). Since AGT-6 and M235T have 
been found to be in strong linkage disequilibrium, with the 
235T variant occurring more than randomly expected with 
the AGT-6 A allele, our results point to the two-loci geno-
type of double homozygotes for both ACE I and a variant 
form of the gene for AGT as potentially being associated 
with a higher risk for CAD since the AAII genotypes had 
high mean CAC levels in both men and women
Genotypic values
GG GA AA SLV
DD 118.67 115.02 107.03 113.57
DI 114.85 117.03 117.08 116.32
II 119.77 115.36 127.65 120.93
SLV 117.76 115.80 117.25
Nonepistatic values
GG GA AA
DD 114.39 112.43 113.89
DI 117.14 115.18 116.63
II 121.75 119.79 121.24
Epistatic values ±standard errors
GG GA AA
DD  4.27±1.03  2.59±0.96  –6.85±1.02
DI  –2.29±1.17  1.85±1.02  0.45±1.35
II  –1.98±1.35  –4.43±1.37  6.41±1.98
t-values (ratio of epistasis value to standard error)
GG GA AA
DD 4.15* 2.69* –6.74*
DI –1.97* 1.81 –0.33
II –1.47 –3.23* 3.24*
Table 4A.  Genotypic, nonepistatic and epistatic values for women for 
systolic blood pressure (in mm Hg) adjusted for age, age2, 
hypertension status, and use of blood pressure lowering 
medications. E2=145.513; F=2.701; P=0.033
* Indicates statistically signiﬁ cant at α=0.05;
SLV – denotes the single locus values.
Genotypic values
GG GA AA SLV
DD 0.23 0.57 0.48 0.42
DI 0.70 0.51 0.83 0.68
II –0.10 0.64 1.58 0.71
SLV 0.28 0.57 0.96
Nonepistatic values
GG GA AA
DD 0.10 0.39 0.79
DI 0.35 0.65 1.04
II 0.38 0.68 1.07
Epistatic values ±standard errors
GG GA AA
DD  0.13±0.07  0.17±0.08  –0.31±0.07
DI  0.35±0.09  –0.14±0.09  –0.21±0.11
II  –0.48±0.10  –0.04±0.10  0.51±0.09
t-values (ratio of epistasis value to standard error)
GG GA AA
DD 2.01* 2.08* –4.64*
DI 3.69* –1.63 –1.98*
II –4.75* –0.37 5.82*
Table 4B.  Genotypic, nonepistatic and epistatic values for women for 
log(CAC area+1) adjusted for age, and age2,systolic blood 
pressure, hypertension status, and use of blood pressure 
lowering medications. E2=0.812; F=2.400; P=0.052.
* Indicates statistically signiﬁ cant at α=0.05;
SLV – denotes the single locus values.
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In addition to the evidence for gene-gene interactions for 
SBP in both men and women and CAC quantity in women 
we also found that men and women differ in their level of 
epistasis between the ACE and AGT polymorphisms. There 
are two main reasons why this result might be expected. First, 
the physiological differences between men and women in 
their lipid metabolism and other metabolic determinants of 
CAC quantity are very likely to affect the mapping function 
between genotype and phenotype. Second, men have much 
higher levels of CAC quantity than women and it’s unlikely 
that the same main effects or epistatic effects of two common 
susceptibility gene mutations will persist across the entire phe-
notypic range of CAC quantity seen in a population.
CONCLUSIONS
In conclusion using a physiological epistasis approach that 
focuses on phenotype values of people with a speciﬁ c multi-
locus genotype and independent of the population frequen-
cy of the genotype class, we identiﬁ ed evidence for epistasis 
not found through the traditional two-way ANOVA approach. 
Our results support the hypothesis that gene-gene interaction 
in the RAS system may be a predisposing factor for a subclin-
ical measure of coronary atherosclerosis in women as well as 
SBP in both men and women. These ﬁ ndings may provide 
some insight into the wide variation in results from studies 
that have focused only on the main effects of these genes.
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